Elevated serum Interleukin-35 levels correlate with poor prognosis in patients with clear cell renal cell carcinoma

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 10, 2015, Pages 18861-18866

  Jin, Lingwei ^a   Xu, Xiaoyan ^a   Ye, Bairu ^a   Pan, Min ^a   Shi, Zhen ^a   Hu, Yunling ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Clear cell renal cell carcinoma; Interleukin 35; Prognosis

Indexed keywords

INTERLEUKIN 35;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 84949670415     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S and Kiemeney LA. The epidemiology of renal cell carcinoma. Eur Urol 2011; 60: 615-621.
3. Spiess PE. Surgical management of locally recurrent renal cell carcinoma post-renal cryoablation: importance of stringent selection criteria. Urol Oncol 2010; 28: 241-242.
4. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS and Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569.
5. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ and Vignali DA. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012; 13: 290-299.
6. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni HT, Artis D, Turk MJ and Vignali DA. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11: 1093-1101.
7. Hu Y, Dong C, Yue Y and Xiong S. In vivo delivery of interleukin-35 relieves coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells. Arch Virol 2014; 159: 2411-2419.
8. Jin P, Ren H, Sun W, Xin W, Zhang H and Hao J. Circulating IL-35 in pancreatic ductal adenocarcinoma patients. Hum Immunol 2014; 75: 29-33.
9. Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, Zhang JA, Wang WD, Xiang WY, Kong B, Wang ZY, Wu BH, Chen XD, He L, Zhang S, Wang CY and Xu JF. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol 2013; 6: 1806-1816.
10. Gu X, Tian T, Zhang B, Liu Y, Yuan C, Shao L, Guo Y and Fan K. Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. Tumour Biol 2015; 36: 2651-6.
11. Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y and Bai XF. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol 2013; 190: 2415-2423.
12. Edge SB and Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474.
13. Choi J, Leung PS, Bowlus C and Gershwin ME. IL-35 and Autoimmunity: a Comprehensive Perspective. Clin Rev Allergy Immunol 2015; [Epub ahead of print].
14. Liu Y, Wu Y, Wang Y, Cai Y, Hu B, Bao G, Fang H, Zhao L, Ma S, Cheng Q, Song Y, Zhu Z, Chang H, Yu X, Sun A, Zhang Y, Vignali DA, Wu D and Liu H. IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects. Leukemia 2015; 29: 939-46.
15. Niedobitek G, Pazolt D, Teichmann M and Devergne O. Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol 2002; 198: 310-316.
16. Dixon KO, van der Kooij SW, Vignali DA and van Kooten C. Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members. Eur J Immunol 2015; 45: 1736-47.
17. Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, Gutchigian S, Frisch A, Hodge I, Jiang X, Wang H and Yang XF. IL-35 is a novel responsive anti-inflammatory cytokine--a new system of categorizing anti-inflammatory cytokines. PLoS One 2012; 7: e33628.
18. Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ and McNeel DG. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol 2012; 189: 5590-5601.